To ask the Scottish Executive what information is held (a) centrally and (b) by each NHS board on the use of (i) bevacizumab, (ii) cetuximab, (iii) lapatinib, (iv) abiraterone, (v) everolimus, (vi) rituximab, (vii) sorafenib, (viii) bendamustine, (ix) fulvestrant and (x) bortezomib in the treatment of cancer.